Press Release
Details
AVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
AVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
“After more than three and a half years of development, we continue to
be on track towards our anticipated introduction of plato™ upgrades into
our clinical programs in the second half of 2019,” said
Dr. Warren is an invited expert panelist at the
- Title: Manufacturing Challenges during
Late Phase Development of Gene Therapy Products - Presenter:
Kim Warren , PhD,AVROBIO - Date/time:
Sunday April 28 ;3 PM - 4:30 PM - Location: Jefferson West
- Title: Automated Gene Modified Cell Production: Concept to Process Verification
- Presenter: Azadeh Golipour, PhD,
AVROBIO - Date/time:
Tuesday April 30 ;1:00 PM - 1:25 PM - Location: Monroe
In several oral presentations at ASGCT, preclinical data will be presented by AVROBIO’s academic collaborators and their colleagues, related to the Company’s gene therapy programs in Gaucher disease and cystinosis.
Gaucher disease ASGCT oral presentation and gene therapy program
An oral presentation will be made at ASGCT with preclinical data results
related to the gene therapy program for Gaucher disease led by
- Title: A Clinical Glucocerebroidase Lentiviral Vector Corrects the Pathology and Clinical Signs in a Mouse Model for Type 1 Gaucher Disease
- Presenter:
Stefan Karlsson , MD, PhD,Lund University ,Sweden - Date/time:
Monday April 29 ;10:45 AM - 11:00 AM - Location: Heights Courtyard 2
Cystinosis ASGCT oral presentations and gene therapy program
Three oral presentations will be made at ASGCT related to the cystinosis
gene therapy program led by
- Title: Toxicology Studies for Hematopoietic Stem & Progenitor Cell Gene Therapy for Cystinosis Revealed an Unexpected Cytotoxicity of Polybrene to the Ctns-/- Sca1+Cells
- Presenters include:
Jay Sharma ,University of California, San Diego - Session: Nonclinical Studies and
Assay Development - Date/time:
Tuesday April 30 ;4:30 PM - 4:45 PM - Location: Heights Courtyard 2
- Title: HSPC Gene Therapy for Cystinosis Remains Effective in Patients Carrying the Large Deletion abolishing SHPK expression
- Presenter:
Spencer Goodman ,University of California, San Diego - Date/time:
Wednesday May 1 ;4:45 PM - 5:00 PM - Location: Holmead
- Title: Hematopoietic Stem Cell Gene Therapy and Lysosomal Cross Correction for Cystinosis
- Presenter: Stephanie Cherqui PhD,
University of California, San Diego - Date/time:
Thursday May 2 ;8:00 AM - 8:30 AM - Location: International Ballroom East
“We believe that Dr. Karlsson’s Gaucher mouse model proof-of-concept
work shows multiple positive preclinical findings, including prevention
and reversal of disease manifestations, as well as improvement trends in
multiple bone parameters. Bone data are important because according to
Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy, prospective products and goals, the therapeutic potential of our product candidates, anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, the design, commencement, enrollment and timing of ongoing or planned clinical trials, and the timing, scope and likelihood of regulatory filings and approvals. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
Any forward-looking statements in this press release are based on
AVROBIO’s current expectations, estimates and projections about our
industry as well as management’s current beliefs and expectations of
future events only as of the date of this release and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, the risk that any one or more of AVROBIO’s
product candidates will not be successfully developed or commercialized,
the risk of cessation or delay of any ongoing or planned clinical trials
of
View source version on businesswire.com: https://www.businesswire.com/news/home/20190426005554/en/
Source:
Investor Contact:
Christopher F. Brinzey
Westwicke Partners
339-970-2843
chris.brinzey@westwicke.com
Media Contact:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com